Insulin secretion has a crucial role in glucose homeostasis, and failure to secrete sufficient insulin is a hallmark of type 2 diabetes. Genome-wide association studies (GWAS) have identified loci contributing to insulin processing and secretion 1,2 ; however, a substantial fraction of the genetic contribution remains undefined. To examine low-frequency (minor allele frequency (MAF) 0.5-5%) and rare (MAF < 0.5%) nonsynonymous variants, we analyzed exome array data in 8,229 nondiabetic Finnish males using the Illumina HumanExome Beadchip. We identified low-frequency coding variants associated with fasting proinsulin concentrations at the SGSM2 and MADD GWAS loci and three new genes with low-frequency variants associated with fasting proinsulin or insulinogenic index: TBC1D30, KANK1 and PAM. We also show that the interpretation of single-variant and gene-based tests needs to consider the effects of noncoding SNPs both nearby and megabases away. This study demonstrates that exome array genotyping is a valuable approach to identify low-frequency variants that contribute to complex traits.
Exome sequencing studies have discovered many low-frequency and rare coding variants 3 that have yet to be examined systematically for association with complex traits. To determine the role of low-frequency coding variants in traits reflecting pancreatic β-cell function, insulin sensitivity and glycemia, we evaluated putative functional coding variants selected from the exome sequences of >12,000 individuals (see Online Methods for a description of the exome array design and content). We successfully genotyped 9,660 Finnish participants in the population-based Metabolic Syndrome in Men (METSIM) study 4 for 247,870 variants on the Illumina HumanExome Beadchip. Clinical characteristics of 8,229 analyzed nondiabetic study participants are summarized in Supplementary  Table 1 . Among 242,071 variants passing quality control, 89,864 (38.1%) were variable in the studied individuals; of these, 71,077 were nonsynonymous, nonsense or located in splice sites (Supplementary Table 2 ). We tested 59,029 variants with MAF > 0.05% for association with insulin processing, secretion and glycemic traits, assuming additive allelic effects and using a linear mixed model to account for relatedness among study participants 5 .
We first evaluated rare and low-frequency coding variants at the nine signals previously identified by GWAS for fasting proinsulin concentration adjusted for fasting insulin (hereafter referred to as fasting proinsulin) 1 . To recognize independent association signals, we carried out conditional analysis adjusting for the known GWAS variants, all of which were represented on the exome array and replicated in METSIM (P < 0.01; Fig. 1 and Supplementary Table 3) . Coding low-frequency variants at the known SGSM2 and MADD loci showed strong evidence of association (P < 5 × 10 −8 ; Table 1 and Supplementary Figs. 1 and 2 ). Previous studies highlighted several possible candidate genes at these loci 1, 6, 7 .
At SGSM2, rs61741902 (MAF = 1.4%, P = 8.9 × 10 −10 ) encodes p.Val996Ile and is independent of the GWAS variant rs4790333 (P conditional = 4.8 × 10 −10 , r 2 = 0.001; Table 1 , Fig. 1 and Supplementary  Table 4 ). SGSM2 (small G protein signaling modulator 2) is a GTPase activating protein (GAP) that interacts with members of the Rab and Rap small G protein pathways and may act in a cascade of Rab-mediated steps in insulin secretory vesicle transport [8] [9] [10] . At rs61741902, the reference valine is well conserved across vertebrates, and the isoleucine substitution is predicted to be damaging (Supplementary Table 5 ). Each additional copy of the minor allele was associated with an average Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion l e t t e r s increase of 0.41 s.d. in fasting proinsulin concentration ( Table 1 and Supplementary  Fig. 2) . However, the proportion of the trait variability explained remained modest (0.47%; 95% confidence interval (CI) 0.22-0.82%) because of the low MAF. Identification of an independent and plausibly functional variant suggests that SGSM2 is the causal gene underlying the common fasting proinsulin GWAS signal.
At MADD, rs35233100 (MAF = 3.7%, P = 7.6 × 10 −15 ) creates the stop codon p.Arg766X, is in modest linkage disequilibrium (LD) with the lead GWAS variant rs7944584 (P conditional = 0.0001, r 2 = 0.17) and is independent of the second GWAS variant rs1051006 (P conditional = 5.0 × 10 −16 , r 2 = 0.02). The nonsense allele of rs35233100, which is associated with decreased proinsulin concentration, is observed only on haplotypes containing the proinsulin-decreasing allele of rs7944584. Adjusting for one variant in a conditional analysis decreased, but did not eliminate, the association for the other (P = 4.9 × 10 −25 , P conditional = 5.7 × 10 −15 for rs7944584; Table 1 and Supplementary Table 4) , suggesting biological contributions from the nonsense variant and an additional causal variant tagged by rs7944584. Of note, the traitdecreasing alleles of the two common GWAS-identified variants rs7944584 and rs1051006 tended to occur on different haplotypes, causing the evidence of association for either SNP to become markedly more significant when adjusting for the other (rs1051006, P = 0.033, P conditional = 2.7 × 10 −8 ; rs7944584, P = 4.9 × 10 −25 , P conditional = 8.3 × 10 −31 ; Supplementary Table 4) . Although the conditional association for the nonsense variant only achieved suggestive significance (P = 0.0001), it provides an especially plausible functional effect. The MADD nonsense variant is located in exon 13 of 36, suggesting that the mRNA would be targeted for nonsense-mediated decay 11 . MADD can act as a guanine nucleotide exchange factor for RAB3 proteins, including RAB3A and RAB3B 12 , which are crucial for insulin exocytosis 13, 14 . Identification of a nonsense variant that contributes to the evidence of association suggests that MADD is a causal gene underlying the common GWAS signals.
LD at chromosome 11 from 46-57 Mb and encompassing MADD has been reported to extend long distances 15 . Consistent with this, we noted significant or suggestive (P < 1 × 10 −5 ) association of fasting proinsulin concentration with nonsynonymous variants up to ~9 Mb away from the lead (noncoding) GWAS variant. Proinsulin-associated variants included rs628524, located ~9 Mb away and encoding p.Ser171Asn in the olfactory receptor OR5M11 (P = 3.7 × 10 −6 for fasting proinsulin and P values as low as 5.0 × 10 −10 for related traits), and rs7941404, located 376 kb away and encoding p.Arg349His in AGBL2 (MAF = 11.8%, P = 4.7 × 10 −21 ). After adjusting for the three MADD variants (rs7944584, rs1051006 and rs35233100), the significances of the associations of the distant variants were reduced by 5-18 orders of magnitude ( Fig. 2 and Supplementary Table 6 ). That these associations were not eliminated suggests that additional variant(s) in this region remain to be identified or that we may be adjusting for imperfect proxies of causal variants. These results also demonstrate that LD should be considered when interpreting GWAS results in this region. For example, the recently reported 16 fasting glucose locus at OR4S1, represented by rs1483121, is in LD (r 2 = 0.19) with the lead and nonsense MADD SNPs ~1 Mb away (Supplementary Table 6 ).
We next tested coding variants across the genome for association with 19 traits measuring pancreatic β-cell function, insulin sensitivity and glucose concentration. We identified two genes harboring low-frequency nonsynonymous variants with new associations for fasting proinsulin concentration: rs150781447, encoding TBC1D30 p.Arg279Cys (MAF = 2.0%, P = 5.5 × 10 −11 ), and rs3824420, encoding KANK1 p.Arg667His (MAF = 3.0%, P = 1.3 × 10 −8 ). The TBC1D30 variant was most strongly associated with late-phase proinsulin-toinsulin conversion (proinsulin area under the curve (AUC) ; P = 1.3 × 10 −16 ), and the KANK1 variant was most strongly associated with early phase proinsulin-to-insulin conversion (proinsulin AUC 0-30 ; P = 1.6 × 10 −9 ) (Table 2, Supplementary Fig. 1 and Online Methods). The TBC1D30 variant effect is large, with each additional copy of the minor allele resulting in an average increase of 0.50 s.d. in the proinsulin AUC 30-120 value ( Table 2 and Supplementary Fig. 2 ). This variant explained 0.94% of the trait variability (95% CI 0.55-1.44%). We also found a new locus for insulin secretion, as measured by the insulinogenic index, represented by nonsynonymous SNPs in PAM (smallest P = 1.9 × 10 −8 ) and PPIP5K2, which are located Previously reported locus New locus Figure 1 Manhattan plot for the fasting proinsulin analysis. Association results of the single-variant analysis (−log 10 P) are plotted against genomic position (NCBI build 37). Previously identified loci are in blue, and loci identified by the current study are in red. Fasting proinsulin concentrations were log transformed and adjusted for fasting insulin, body mass index, age and age squared. VPS13C/C2CD4A/B means VPS13C, C2CD4A or C2CD4B. Table 2 and Supplementary Figs. 
1-3).
Common SNPs at GPSM1, HNF1A and ABO that have been previously associated with other traits are here associated with insulin secretion or β-cell function in nondiabetic individuals ( Table 2 and Supplementary Fig. 3 ). GPSM1 p.Ser391Leu is in LD with the noncoding SNP rs3829109 (r 2 = 0.69), which has been previously associated with fasting glucose concentration 2 . At ABO, the T allele of rs505922 is a proxy for the O blood group and has been associated with diverse phenotypes, including decreased pancreatic cancer risk 17 and increased risk for duodenal ulcers 18 . Near HNF1A, rs2650000 was previously associated with low-density lipoprotein cholesterol 19 and C-reactive protein 20 ; other HNF1A variants are associated with MODY3 (MIM#600496) and type 2 diabetes risk 21 .
TBC1D30 and KANK1 both function in G-protein signaling and are strong biological candidates for affecting fasting proinsulin concentration. TBC1D30 (encoding TBC 1 domain family, member 30) encodes a GAP protein that probably regulates the activity of specific Rab GTPases, including RAB3A 22 and RAB8A 23 . Rab3A knockout mice show a severe decrease in glucose-induced first-phase insulin release and a 75% decrease in plasma insulin concentrations without insulin resistance 24 . The reference arginine at rs150781447 is well conserved across vertebrate species, and the cysteine substitution is predicted to be damaging 25 (Supplementary Table 5 ). The variant is located within a Rab-GAP domain and the Kozak sequence of one TBC1D30 isoform and may alter translation initiation.
KANK1 (KN motif and ankyrin repeat domain-containing protein 1) has a role in cytoskeleton formation by regulating actin polymerization 26 , and it negatively regulates Rac1 and RhoA G protein signaling, pathways that have been implicated in insulin secretion 27, 28 . At rs3824420, the reference arginine is not well conserved across species, and the protein structure is predicted to tolerate the histidine substitution without an effect on function; this variant may still affect KANK1 or may tag another nearby variant. Although rs3824420 has a low frequency in Europeans (MAF = 2.9% in Finns), it is common in east Asians (MAF = 16%; Supplementary Table 7) .
PAM encodes the peptidylglycine α-amidating monooxygenase, an essential secretory granule membrane enzyme that catalyzes α-amidation of peptide hormones such as proinsulin 29 . Older mice heterozygous for Pam deficiency have glucose intolerance 30 . At rs35658696, the reference aspartic acid is well conserved across vertebrates and is located in one of the catalytic domains, and the glycine substitution is predicted to be damaging (Supplementary Table 5 ). The nearby gene PPIP5K2 is involved in cell signaling but has no known connection to insulin pathways. At rs36046591 in PPIP5K2, which is in near-perfect LD (r 2 = 0.997) with rs35658696, the glycine substitution is predicted to be tolerated, and the reference serine is not well conserved across species. This difference suggests that the PAM variant, rather than the PPIP5K2 variant, is causal at the locus, but it is impossible to dissect the two genetically.
We then carried out gene-based tests to further investigate the role of rare and low-frequency variants in insulin secretion and processing. Gene-based tests offer an alternative to single-variant tests, which are often underpowered to detect association with rare variants. We performed our tests on trait residuals adjusted for relatedness and covariates (Online Methods). To address the impact of less common and rare variants, we considered only SNPs with MAF < 3% or MAF < 1%. In total, we tested 10,515 genes having at least two such variants using the sequence kernel association optimal (SKAT-O) test 31 . Identified by common variants The data shown are based on an analysis of 8,103-8,191 (depending on phenotype availability) nondiabetic males. The lead trait is the trait with smallest P value. Traits were log transformed and adjusted for BMI, age and age squared. Effects are reported for the minor allele. The SNPs at PAM and PPIP5K2 are tightly linked (D ′ = 0.999, r 2 = 0.997).
a Positions are given in bp from NCBI build 37, with allele labels from the forward strand. b Effect sizes are given in s.d. units ± s.e.m. Chr., chromosome.
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We found significant associations between fasting proinsulin concentration and TBC1D30, SGSM2 and ATG13 when using a MAF upper bound of 3% ( Table 3 and Supplementary Fig. 4) ; by conditioning on the low-frequency variants detected by single-variant analysis, we demonstrated that these signals are driven by low-frequency variants. After adjusting for the common and nonsense variant signals at MADD, the significance of the association at ATG13, ~609 kb away, decreased by five orders of magnitude ( Table 3) , showing that this signal is partially driven by the MADD variants and suggesting that other variants in this region remain to be identified or that we may be adjusting for imperfect proxies of the causal variant. We detected no additional associations with other traits, including type 2 diabetes (data not shown).
In summary, we identified two low-frequency coding variants in genes at known loci and three new genes with low-frequency variants associated with insulin processing or secretion. At least four of these genes have roles in G-protein signaling (Supplementary Fig. 5 ). We show that the interpretation of both single-variant and genebased tests needs to consider the effects of distant common SNPs, an especially important consideration when exome sequence data are analyzed without data on the surrounding noncoding regions. Although regions of long-range LD are unusual, at least 24 have been reported 15 to extend >1 Mb in Europeans, a distance frequently used to claim independence of association signals in GWAS meta-analyses. Several of the identified exome array variants are plausibly functional, although ~25% and ~28% of low-frequency nonsynonymous variants on the exome array were annotated as conserved and plausibly damaging, respectively (Supplementary Table 2) , and the exome array does not provide complete coverage of all functional variants at each locus. This study was also limited in its ability to look at very rare variants because of the content of the exome array. Although sequencing will still be required to completely assess variants associated with insulin processing, secretion and glycemic traits, this study provides proof of principle that exome array genotyping is a powerful approach to identify low-frequency functional variants and fine map GWASidentified loci in complex traits.
URLs. Exome array design, http://genome.sph.umich.edu/wiki/ Exome_Chip_Design; Complete Genomics 69 Genomes Data, http://www.completegenomics.com/public-data/69-Genomes/; The 1000 Genomes Project, www.1000genomes.org/; PLINK, http:// pngu.mgh.harvard.edu/~purcell/plink/; SMARTPCA, http://genetics. med.harvard.edu/reich/Reich_Lab/Software.html; EMMAX, http:// genetics.cs.ucla.edu/emmax/; GenABEL, http://www.genabel.org/.
METHodS
Methods and any associated references are available in the online version of the paper. Fasting proinsulin concentrations were log transformed and adjusted for fasting insulin, BMI, age and age squared. Residuals were adjusted for relatedness, and gene-based testing was carried out using the SKAT-O test (Online Methods). This analysis was based on 8,224 participants. Reported associations were significant after Bonferroni correction testing 19 traits for 10,515 genes (with a significance threshold of P = 2.5 × 10 −7 ).
oNLINE METHodS
Study participants. We attempted exome array genotyping of 9,717 participants in the METSIM study 4 . Male study participants were randomly selected from the population register of Kuopio, eastern Finland (population 95,000). Participants undertook a 1-d outpatient visit to the Clinical Research Unit at the University of Kuopio. Participants with diagnosed type 1 or type 2 diabetes (previously diagnosed, on diabetes medication, fasting glucose ≥7 mmol/l or 2-h glucose ≥11.1 mmol/l) were excluded from the quantitative trait analysis. Clinical characteristics of the nondiabetic study participants are provided in Supplementary Table 1 . The study was approved by the ethics committee of the University of Kuopio and Kuopio University Hospital; informed consent was obtained from all study participants.
Oral glucose tolerance testing and laboratory measurements. Clinical testing was performed after a 12-h overnight fast. A 2-h oral 75-g glucose tolerance test (OGTT) was performed with blood samples drawn at 0, 30 and 120 min for measurement of plasma proinsulin, insulin and glucose concentrations. Plasma-specific proinsulin (Human Proinsulin RIA kit, Linco Research, St. Charles, MO; no crossreaction with insulin or C-peptide) and insulin (ADVIA Centaur Insulin IRI, 02230141, Siemens Medical Solutions Diagnostics, Tarrytown, NY; minimal crossreaction with proinsulin or C-peptide) were measured by immunoassay, and plasma glucose was measured by enzymatic hexokinase photometric assay (Konelab System Reagents, Thermo Fisher Scientific, Vantaa, Finland). Indices of insulin sensitivity included HOMA of insulin resistance (HOMA-IR) 34 and the Matsuda ISI 36 . Associations with fasting and 120-min glucose were also tested. Supplementary Figure 6 shows correlations among traits. We calculated AUC measures using the trapezoid rule.
Phenotypes
Exome array. The Illumina HumanExome-12v1_A Beadchip includes 247,870 markers focused on protein-altering variants selected from >12,000 exome and genome sequences representing multiple ethnicities and complex traits. Nonsynonymous variants had to be observed three or more times in at least two studies, and splicing and stop-altering variants had to be observed two or more times in at least two studies. Additional array content includes variants associated with complex traits in previous GWAS, HLA tags, ancestryinformative markers, markers for identity-by-descent estimation and random synonymous SNPs. Details about SNP content and selection strategies can be found at the exome array design webpage (see URLs).
Genotyping and quality control. In total, 9,717 study samples, 104 blind duplicate samples and 116 HapMap samples of different ethnicities were genotyped at the GRCF at Johns Hopkins Institute of Genetic Medicine. Genotype calling was carried out using Illumina's GenTrain version 1.0 clustering algorithm in GenomeStudio version 2011.1. Cluster boundaries were determined using study samples. After clustering, 5,574 nonautosomal and 3,379 autosomal variants identified through filtering strategies developed at GRCF were manually reviewed, and clusters were edited as necessary.
After technical failure and marker-level quality control, 242,458 of 247,870
(97.8%) attempted markers were successfully genotyped and had call rates >95% (average call rate, 99.95%).
We evaluated genotyping quality using concordance rates for HapMap samples genotyped in our study and either (i) sequenced by Complete Genomics or the 1000 Genomes Project (on-target regions of integrated phase 1 release; see URLs) or (ii) genotyped on the Illumina HumanOmni2.5 Beadchip by the 1000 Genomes Project. These comparisons were based on 60,574, 117,063 and 39,056 overlapping variants and 17, 49 and 86 individuals, respectively. Overall concordance rates were 99.933%, 99.972% and 99.956% for the Complete Genomics data, 1000 Genomes sequence data and HumanOmni2.5 Beadchip data, respectively. Considering the external data as truth, concordance rates for homozygous genotypes were 99.982%, 99.987% and 99.974% and were 99.678%, 99.529% and 99.886% for heterozygous genotypes, respectively.
In total, 9,660 of 9,717 (99.4%) individuals were successfully genotyped (call rate >98%). For the 242,458 SNPs that passed quality control, genotype concordance among the 104 blind duplicate sample pairs was 99.998%. Three sex-mismatched individuals were identified and excluded from subsequent analyses. One individual per pair of six known twin pairs, and six unexplained apparent duplicates were excluded.
We carried out principal components analysis (PCA) twice, once excluding HapMap samples to identify population outliers and once including HapMap samples to help interpret outliers. To avoid artifactual results caused by family relatedness 37 , we computed principal components using SNP loadings estimated from a subset of 7,304 not-close relatives. We defined close relatives as those for whom the estimated genome-wide identity-by-descent (IBD) proportion of alleles shared was >0.10. We estimated IBD sharing using PLINK's '-genome' option 38 and carried out PCA using SMARTPCA 37 on an LD-pruned set of 22,464 autosomal SNPs obtained by removing large-scale high-LD regions 15, 39 , SNPs with MAF < 0.01 or SNPs with Hardy-Weinberg equilibrium (HWE) P < 10 −6 and carrying out LD pruning using the PLINK option '-indep-pairwise 50 5 0.2' . Inspecting the first ten principal components, we identified 12 population outliers, 9 of whom had self-reported non-Finnish ancestry; we excluded these 12 individuals from subsequent analyses. After further removal of 25 individuals with diagnosed type 1 diabetes, 1,376 individuals with type 2 diabetes and 3 individuals with missing phenotypes, 8,229 individuals remained for quantitative trait analysis.
Statistical analyses.
Single-variant analysis. We tested for trait-SNP associations assuming an additive genetic model using a linear mixed model to correct for relatedness using EMMAX 5 . We excluded SNPs with MAF < 0.05% or HWE P < 10 −6 . To reduce the impact of outliers, we log transformed traits with skewed distributions and then Winsorized all traits at 5 s.d. from the mean. All traits were adjusted for BMI, age and age squared before association testing. We analyzed both untransformed residuals and rank-based inverse-normal-transformed residuals to assess the robustness of association results to distributional assumptions. As no appreciable differences were observed between the two analyses, we report the results for the untransformed residuals. We then visually inspected genotype cluster plots and checked HWE P values for all described variants. The lowest HWE P value for a reported newly associated variant was 0.09.
Population stratification. To correct for population stratification, we modeled population structure as part of the random effects indistinguishable from the relatedness effect 5 . To investigate residual population stratification, we calculated genomic control inflation factors 40 and inspected quantile-quantile plots for test statistics both before and after removal of established and newly discovered loci (2-Mb segments centered on the lead SNPs) (Supplementary Fig. 7) .
Conditional analysis. To identify additional association signals after accounting for the effects of known and newly discovered trait loci, we carried out conditional analyses in which we included the allele count at the lead SNP(s) at the conditioning loci as covariate(s). To allow discovery of more than two association signals per locus, we used a stepwise procedure in which additional SNPs were added to the model according to their conditional P value, as programmed in EMMAX 5 . We estimated the LD metrics r 2 and D′ using 9,633 individuals from METSIM who passed genotyping quality control. LD with SNPs not included on the exome array was determined on the basis of whole-genome sequence data for 1,479 northern European individuals.
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Gene-based analysis. For gene-based testing, we used the SKAT-O 31 test, which encompasses burden tests and SKAT 41 as special cases. SKAT-O has been shown to perform well under a range of scenarios, including scenarios in which protective, deleterious and null variants are present and those in which a large number of variants are causal and associated in the same direction 31 . To account for relatedness, we adopted an approach similar to GRAMMAR 42 by first obtaining trait residuals adjusted for relatedness using GenABEL 43 and then carrying out gene-based testing. We performed analyses using default weights 31 and MAF upper bounds of 1% and 3% for the combination of nonsynonymous, stop-altering and splice-site variants. In total, 10,515 genes with at least two variants were tested. The results of the naive SKAT-O analysis and the analysis adjusted for relatedness were highly correlated ( Supplementary  Fig. 8 ). To evaluate whether common or low-frequency SNPs associated with the trait in the single-variant analysis could account for a gene-based test signal, we also carried out conditional analyses by including the allele count at such SNP(s) as covariate(s).
Statistical significance. We declared a single variant-trait association significant if the nominal P value was <4.46 × 10 −8 , corresponding to a Bonferroni correction for 1,121,551 tests (19 phenotypes × 59,029 variants). We declared a gene-based test association significant if the nominal P value was <2.50 × 10 −7 , corresponding to a Bonferroni correction for 199,785 tests (19 phenotypes × 10,515 genes).
Annotation. We annotated variants relative to GENCODE version 7 coding transcripts 44 using in-house developed software (unpublished). Amino acid substitution positions are relative to the canonical UniProt protein sequence 45 .
